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In order to decide whether a new treatment should be used in patients, a robust estimate of
efficacy and toxicity is no longer sufficient. As a result of increasing healthcare costs across
the globe healthcare payers and providers now seek estimates of cost-effectiveness as well.
Most trials currently being designed still only consider the need for prospective efficacy and
toxicity data during the development life-cycle of a new intervention. Hence the cost-effec-
tiveness estimates are inevitably less precise than the clinical data on which they are
based. Methods based on decision theory are being developed by health economists that
can contribute to the design of clinical trials in such a way that they can more effectively
lead to better informed drug funding decisions on the basis of cost-effectiveness in addi-
tion to clinical outcomes. There is an opportunity to apply these techniques prospectively
in the design of future clinical trials. This article describes the problems encountered by
those responsible for drug reimbursement decisions as a consequence of the current drug
development pathway. The potential for decision theoretic methods to help overcome
these problems is introduced and potential obstacles in implementation are highlighted.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
For a drug license to be granted, a manufacturer will generally
be required to prove the safety and efficacy of a drug for a gi-
ven indication. The increasing costs of healthcare around the
world have led to healthcare providers and payers requiring
further evidence relating to value for money. Almost all devel-
oped healthcare systems have now established reimburse-
ment processes to formally assess this evidence and make
recommendations on how new drugs should be paid for
(reimbursed).1 Economic evaluation provides a means to as-
sess whether new treatments represent value for money.
The need to demonstrate cost-effectiveness has beener Ltd. All rights reserved
.
Hall).described as the ‘fourth hurdle’ after quality of manufacture,
safety and efficacy.2
Overcoming the fourth hurdle is problematic for all con-
cerned. Clinical trials of new cancer drugs are designed pri-
marily to meet the requirements of licensing authorities
such as the European Medicines Agency in Europe or the US
Food and Drug Administration. Despite attention from the
academic community separating the design characteristics
of pragmatic and explanatory trials,3 it is rare for such trials
to collect the information required for a robust economic eval-
uation. The ability of reimbursement authorities to make a
fully informed adoption decision is, therefore, often compro-
mised by uncertainty in the evidence for cost-effectiveness..
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type of decision making can face was seen with the introduc-
tion of trastuzumab (Herceptin) for early breast cancer
which gained a license as adjuvant treatment in 2006. Clinical
efficacy was proven beyond reasonable doubt but estimates of
cost-effectiveness accepted by the UK reimbursement author-
ity the National Institute for Health and Clinical Excellence
(NICE) were highly uncertain due to the necessary extrapola-
tion and assumptions beyond trial-based evidence.4 This led
to delays in approval with consequent public outcry and also
a formal appeal by a local healthcare provider against the fi-
nal positive decision.5,6
Despite difficulties in assessing cost-effectiveness, when
faced with the challenge of maximising the health of the pop-
ulationwithin the constraints of a fixed public healthcare bud-
get, it is a vital consideration. Therefore, if patients are to
access new drugs through a publicly funded system, cost-
effectiveness must be considered along with other social and
political factors prior to a positive reimbursement decision.7
2. Cost-effectiveness modelling and the drug
development pathway
While trial-derived data on all aspects of clinical and eco-
nomic evidence might be considered optimal, it is frequently
unavailable. This necessitates the use of decision modelling
to bring together evidence from other sources such as obser-
vational studies to inform a cost-effectiveness estimate.8 A
modelling exercise can also facilitate estimation of cost-effec-
tiveness in an actual patient population rather than a selected
trial population. Fig. 1 illustrates a typical decision model for
this purpose. Several countries use such a decision model at
the time a reimbursement decision needs to be made, which
is normally after a drug has received licensing approval (Fig. 2).
The ability of a reimbursement decision maker to make a
fully informed adoption decision which considers cost-effec-
tiveness or value may be compromised for a number of short-
falls in evidence. When considering clinical trial data, theseFig. 1 – A decision-analytic model used for cost-effective-
ness analysis. Multiple aspects of research contribute to the
model as input parameters. The model produces an output
as average life years or average quality-adjusted life years
per patient as well as average cost per patient. These
together form the measure of cost-effectiveness, the incre-
mental cost-effectiveness ratio (ICER) between standard care
and a new intervention.can include short follow-up, a highly selected patient popula-
tion and a lack of prospectively collected real cost data. This
could be rectifiable but for an often experienced inability to
generate adequate evidence for cost-effectiveness assess-
ment at this time point. This may be because once a drug is
licensed and accepted as clinically efficacious further re-
search becomes difficult. For example, randomised trials
attempting to refine treatment regimens or collect additional
data will often fail to recruit as patients are unwilling to risk
randomisation that may deny them the drug as licensed. Fur-
thermore, trials of newer agents tend to be more attractive to
clinical investigators than studies designed to answer ques-
tions relating to population rather than individual patient
benefit. In the case of trastuzumab for early breast cancer,
these problems have hindered trials which are attempting
to assess shorter treatment durations as well as collect in-
depth quality of life and economic data after licensing ap-
proval has been granted.9
Despite this, a decision still has to be made. It is therefore
accepted that an adoption decision should be made on the
basis of the expected cost-effectiveness given existing infor-
mation (i.e. choose the treatment strategy that is most likely
to be cost-effective rather than require a p-value of 0.05 for
cost-effectiveness). The greater the level of uncertainty in
the evidence themore likely it becomes that a reimbursement
authority will make an incorrect reimbursement decision. An
incorrect decision wastes resources that could have been
used for health gain elsewhere (opportunity cost). Further
research aimed at reducing uncertainty consequently has
value, meaning that there will be value in delaying the
decision and conducting further research.10
There is thus a need to avoid delay in reimbursement deci-
sion making by generating sufficient evidence for a reim-
bursement decision alongside initial safety and efficacy data
if patients are to have rapid access to new treatments. How-
ever, there is substantial uncertainty regarding how trials
should be designed to provide such evidence, which will be
unique to each drug, depending on other available informa-
tion. It has therefore been suggested that the type of decision
models used for economic evaluation could be used earlier in
the drug development process to identify additional require-
ments for robust cost-effectiveness analysis (Fig. 3).11–13 Such
models would synthesise all the available evidence prior to
initiation of a pivotal trial and identify critical uncertainties
in the evidence from the perspective of reimbursement. For
example, there may be plenty of evidence about the costs of
common toxicities from phase II studies or studies in differ-
ent cancer types such that gathering further detailed evi-
dence would be of little value. For a new anti-cancer drug
there will undoubtedly be value in efficacy research, but there
might also be a value in researching impact on quality of life
and costs of care. As an alternative example, consider a study
measuring the benefit of a new anti-emetic. The cost (and
size) of a trial with a survival endpoint would be prohibitive
and unnecessary, whereas measuring QoL and the reduction
in costs of controlling emesis would be much more beneficial.
This might seem obvious, but an explicit framework for iden-
tifying howmuch of each type of research would be useful for
a given decision problem has much to offer when considering
more subtle aspects of research design.
Fig. 2 – Current drug development and approval process for new pharmaceuticals. Further research is required to inform cost-
effectiveness estimates after a licensing decision has beenmade. The result is a delay to the reimbursement decision and the
act of licensing a drug can hinder further research.
Fig. 3 – Suggested drug development process. By undertaking a decision modelling exercise prior to the phase III trial,
research can be tailored to allow an adequately informed reimbursement decision without the need for further evidence
generation.
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design
The overwhelming objective of medical research from a soci-
etal perspective should be population health gains from new
interventions. This requires consideration of monetary
expenditure on research in addition to expected clinical
gains, given that similar expenditure elsewhere could poten-
tially provide greater health gains. Current methods for public
research prioritisation are far from transparent, but in general
rely on pre-defined criteria which are open to interpretation
within peer review and panel discussion procedures. An ex-
plicit and reproducible framework that complements this
process is required to estimate the potential population-level
benefit gained by specific research, including the benefits of
reducing reimbursement decision uncertainty.
A number potential solutions have been proposed.14 Most
are a variant of the decision-analytic approach. During the
last decade interest in research prioritisation within UK
health economics has focussed on value of information
(VoI) methods.15 These rely on decision theory and the Bayes-
ian statistical paradigm. They were developed in the 1950s
and 60s for business application and have subsequently been
used within food standards, environmental and engineering
fields.16–23 The last decade has seen them developed for
health research prioritisation in the setting of health technol-
ogy assessment.24–27
A VoI analysis can be conducted using a decision model at
any point in the drug development process. It has been lik-
ened to sensitivity analysis which, used alone, can indicate
the magnitude of influence of different aspects of research
on outcomes. VoI methods provide an advantage over sensi-
tivity analysis by providing a quantifiable estimate of societalpayoff for aspects of research.28 Theoretically, the VoI is the
highest amount a decision maker would be willing to pay
for information prior to making a decision. Within a health-
care context this allows precise monetary value to be attrib-
uted to the information that can inform reimbursement
decision making. This value reflects the opportunity cost to
society (benefits foregone by patients) of making an incorrect
reimbursement decision, multiplied by the probability of
making that incorrect decision (derived from the uncertainty
around current evidence). The decision uncertainty is the risk
of making the wrong decision. The ‘‘expected value of perfect
information’’ (EVPI) can be calculated for a given decision (e.g.
the decision to fund a new drug) and represents an upper
bound on the value of conducting research to inform this
decision. VoI is a simple idea, but its conceptual origins are
out-with classical medical statistics, thus requiring a cogni-
tive shift for those who traditionally dictate methods in drug
development research.
So how can a VoI analysis positively influence research de-
sign at the time of a phase III drug trial? Fig. 4 presents a
hypothetical output from a VoI analysis on the basis of a deci-
sion model constructed at the pre-phase III time point. This
shows the relative value of conducting research on different
aspects of the evidence contributing to a cost-effectiveness
endpoint. This can be used to tailor research designs to re-
duce uncertainty in the most valuable areas of evidence.
The VoI approach can take into account the number of future
patients likely to be affected by a disease, potential clinical
benefits from treatment and costs to payers, with each of
these parameters contributing to an overall estimate of the
treatment’s value.
While EVPI calculations are useful, they still have limita-
tions. The EVPI should be the maximum a decision maker is
Fig. 4 – Value of Information analysis output. In this hypothetical example prior to a phase III trial there is value in research
into efficacy, in particular long-term follow-up. A quality of life study is also worthwhile but research into costs or toxicity is
less of a priority.
Fig. 5 – Hypothetical VoI calculation to determine the
optimal sample size of a trial for a cost-effectiveness
endpoint. The total cost of the research comprises an up-
front cost and a per-patient cost. The expected value of
sample information (EVSI) reaches an optimal level at a
sample size of approximately 800 patients. At this point the
expected net gain of sampling (ENG) is also at a maximum
and is the EVSI minus the total cost of research. This
represents the overall benefit (financial and health) of the
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aspiration rather than a realistic goal. What is really needed
is an estimate of payoff for a given research proposal. To meet
this need, the same framework can be extended to calculate
the expected value of sample information (EVSI). EVSI calcu-
lations are currently technically difficult as outlined below
but in the future as methods advance they should have a lot
to offer. The EVSI estimates the reduction in the cost of uncer-
tainty induced by sampling (further research). By subtracting
the cost of sampling from the EVSI the expected net gain
(ENG) of the research can be calculated. By calculating the
ENG for a variety of proposed trial designs (considering as-
pects such as sample size or length of follow-up) the preferred
design can be selected.29,30 A hypothetical representation of
an EVSI calculation for a trial sample size is shown in Fig. 5.
An optimal sample size could be specified to inform a second-
ary cost-effectiveness endpoint, complementing the tradi-
tional sample size calculation based on the estimated effect
size (and required p-value) of the primary endpoint. Such cal-
culations might also indicate value in conducting a smaller
additional sub-study such as a cost or quality of life sub-study
on a portion of the total study sample.research. Such a calculation might complement a traditional
power calculation.
4. Is decision theory ready to inform trial
design?
Value of information methods based on decision modelling
has recently been the focus of intense development by health
economists and Bayesian statisticians in attempts to over-
come a number of challenges their use poses:
4.1. Structuring a decision problem
It is important to adequately represent the clinical pathway
upon which a decision model is based. All aspects of a prob-
lem need to be addressed without creating an over-complex
model and resulting in analytical error. Adequately represent-
ing structural uncertainty remains difficult and omission of a
key factor can lead to oversight in attributing priorities for re-
search. This is a problem for any type of model-based eco-nomic evaluation, not just for research prioritisation.31
Sensitivity analysis around alternative model structures is
the current best solution.
4.2. Evidence synthesis and model parameterisation
This includes, for example, the challenges of eliciting prior
information from experts to inform model parameters where
empirical research has not yet taken place. There is also a
requirement to consider correlation between different param-
eters of a model and to accurately extrapolate short-term
data over a relevant time horizon. Reliance on surrogate out-
comes and transferability of data between healthcare settings
also pose challenges.32
2678 E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 2 6 7 4 –2 6 8 04.3. Computational and statistical challenges
EVPI and EVSI can be calculated by a variety of methods
depending on the validity of assumptions about model linear-
ity and normality.33–35 A series of papers by Willan and Ecker-
mann have developed purely parametric methods to a high
theoretical level although their use with the complex models
required for most health technology assessment may be lim-
ited.36,37 Non-parametric EVSI calculation poses a much high-
er computational burden and, although developments are on-
going, much more work is needed.38,39
4.4. Adoption by regulatory organisations and
reimbursement agencies
It is reimbursement authorities and other regulators who
have the power to ensure these methods are implemented,
perhaps with cooperation from licensing authorities. It will
also be their responsibility to ensure that adequate analytic
standards are adhered to. A number of challenges that must
be overcome before they can do this have been pointed out.
These include the problems associated with reversing a deci-
sion after the emergence of further information, problems
with conducting further research after an intervention is
adopted as routine care and the potential incentive for juris-
dictions to wait for others to conduct research (free-rider
problems).25
4.5. Adoption by public research commissioners and
clinical trialists
The framework for economic evaluation in healthcare that
has emerged over the last 30 years is unfamiliar to much of
the clinical research community. There remains mistrust of
decision modelling which can seem opaque to those without
technical expertise. Traditional methods for creating hypoth-
eses and designing trials have developed over many decades.
Clinicians and statisticians have learnt to work together to
enhance the internal validity of clinical research: adoption
of an alternative framework unsurprisingly faces some resis-
tance. To be effective, clinicians, trialists and health econo-
mists must work together to deliver this alternative
paradigm that acknowledges the reality of opportunity cost.
Realistic and understandable applied examples in oncology
are needed to demonstrate to a relevant audience how the
methods described can improve the design of important drug
trials.
4.6. Industrial drug development
Prioritising or designing research on the basis of societal ben-
efit might seem irrelevant in the context of industry-funded
drug research, when the objective is profit maximisation
rather than societal health benefit. However, ensuring that
pharmaceuticals research adequately informs public reim-
bursement decision makers is likely to work to the advantage
of companies seeking to speed up market access. The provi-
sion of clear goal posts in this respect, as is likely to develop
with the advent of value-based pricing mechanisms, gives
the industrial research designer a clear incentive to generateunambiguous cost-effectiveness-based outcomes. Indeed, as
regulators move towards formally demanding cost-effective-
ness evidence, there will be a need for companies to improve
the efficiency of their research programmes in meeting these
endpoints in addition to purely clinical outcomes.40,41
5. Conclusion
The potential of VoI methods is clear from recent pilot stud-
ies.42 VoI analyses have been successfully conducted in non-
cancer settings where they have presented priorities for fur-
ther research as part of on-going public research pro-
grammes.43–49 Steps are being taken to introduce these
methods into the decision-making process operated by NICE.
In the UK the renegotiated Pharmaceuticals Pricing Regula-
tion Scheme is likely to lead to greater requirements for eco-
nomic outcome measures for new drugs. Future drug
reimbursement decisions and drug pricing negotiations are
likely to be conditional on the generation of further evi-
dence.50 Risk sharing schemes are being utilised in Europe
as a stop-gap measure to address the problem of decision
uncertainty. Their effectiveness remains unproven and they
are not a solution.51 Value-based pricing is now being pro-
moted as the future of pharmaceuticals pricing. Other coun-
tries, including the US, Australia and Canada, are exploring
decision modelling and VoI analysis as a potential research
prioritisation strategy in the light of this.52 Recent healthcare
reform in the US places much emphasis on value for money,
and countries across Europe are developing their own frame-
works attempting to rationalise spiralling healthcare costs. It
is clear that value not just efficacy will be a key requirement
for the introduction of future drug innovations. Efficient re-
search to determine value will therefore be vital.
An explicit framework for research priority setting is long
overdue and decision theoretic methods show much promise
as the foundation for a solution. They allow estimation of the
value of conducting research and can help ensure that suffi-
cient evidence is generated for adequately informed reim-
bursement decisions at, or close to, the time of licensing. In
the coming years it should be possible for clinical trialists,
working with health economists, to establish in advance
how much and what type of evidence are required to inform
a drug adoption decision, thereby improving the likelihood
that effective therapies will be available for their patients.Authors contributions
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